| Literature DB >> 28223236 |
Thomas F Martens1, Karen Peynshaert2, Thaís Leite Nascimento3, Elias Fattal3, Marcus Karlstetter4, Thomas Langmann4, Serge Picaud5, Jo Demeester2, Stefaan C De Smedt2, Katrien Remaut2, Kevin Braeckmans6.
Abstract
Intravitreal administration of nanomedicines could be valuable for retinal gene therapy, if their mobility in the vitreous and therapeutic efficacy in the target cells can be guaranteed. Hyaluronic acid (HA) as an electrostatic coating of polymeric gene nanomedicines has proven to be beneficial on both accounts. While electrostatic coating provides an easy way of coating cationic nanoparticles, the stability of electrostatic complexes in vivo is uncertain. In this study, therefore, we compare electrostatic with covalent coating of gene nanocarriers with HA for retinal gene therapy via intravitreal administration. Specifically, DOTAP:DOPE/plasmid DNA lipoplexes coated with HA are evaluated in terms of intravitreal mobility using a previously optimized ex vivo model. We find that both electrostatic and covalent HA coating considerably improve the mobility of the lipoplexes in the vitreous humor of excised bovine eyes. In addition we evaluate in vitro uptake and transfection efficiency in ARPE-19 cells. Contrary to PEGylated lipoplexes it is found that HA coated lipoplexes are efficiently internalized into ARPE-19 cells. Covalent HA-coated lipoplexes had an 8-fold increase of transgene expression compared to the uncoated lipoplexes. We conclude that covalent HA-coating of gene nanomedicines is a promising approach for retinal gene therapy by intravitreal administration.Entities:
Keywords: Hyaluronic acid; Intravitreal administration; Lipoplexes; Nanoparticle mobility; Retinal gene therapy
Mesh:
Substances:
Year: 2017 PMID: 28223236 DOI: 10.1016/j.ejps.2017.02.027
Source DB: PubMed Journal: Eur J Pharm Sci ISSN: 0928-0987 Impact factor: 4.384